<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46929">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938027</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-TAME</org_study_id>
    <secondary_id>NCC-1210170</secondary_id>
    <nct_id>NCT01938027</nct_id>
  </id_info>
  <brief_title>The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision</brief_title>
  <official_title>A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <authority>Korea: National Cancer Center</authority>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluation of the safety and the efficacy of transanal total
      mesorectal excision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have their rectal cancer removed using a technique combining surgery through
      the anus and standard laparoscopy. Transanal visualization will be using endoscopy.  At the
      end of the procedure, the rectum will be removed though the anus or ileostomy formation
      site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be
      created, which is standard of care following surgery for this type of cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total Mesorectal Excision(TME) quality</measure>
    <time_frame>1-5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The quality of the mesorectum was determined using pathology reports and scored using three grades:
Complete: intact mesorectum with only minor irregularities of a smooth mesorectal surface. No defect is deeper than 5 mm, and there is no coning toward the distal margin of the specimen. There is a smooth circumferential resection margin on slicing.
Nearly complete: moderate bulk to the mesorectum, but irregularity of the mesorectal surface. Moderate coning of the specimen is allowed. At no site is the muscularis propria visible, with the exception of the insertion of the levator muscles.
Incomplete: little bulk to mesorectum with defects down onto muscularis propria and/or very irregular circumferential resection margin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day postoperative complications, No. of harvested LN</measure>
    <time_frame>1-5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Oncologic outcome(2-year local recurrence free survival, 5-year survival)</measure>
    <time_frame>1-5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Transanal total mesorectal excision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopy-assisted transanal total mesorectal excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transanal total mesorectal excision</intervention_name>
    <description>Laparoscopy-assisted transanal total mesorectal excision</description>
    <arm_group_label>Transanal total mesorectal excision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 20-80 years

          -  biopsy-proven adenocarcinoma of the rectum

          -  clinical staging, (T1 or T2 or T3) with N0M0

          -  Rectal cancer located 4-12 cm from the anal verge

          -  ECOG performance status 2 or less

        Exclusion Criteria:

          -  Synchronous colon cancer or other malignancy

          -  Obstructing rectal cancer

          -  Pregnant or breast-feeding

          -  Receiving any other study agents

          -  Fecal incontinence

          -  History of prior colorectal cancer or inflammatory bowel disease

          -  BMI &gt; 30

          -  T3 rectal cancer not treated preoperatively with full-course chemoradiation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hwan Oh, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCC,Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Hwan Oh, MD, PHD</last_name>
    <phone>+82‐31‐920‐1637</phone>
    <email>jayoh@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dae Kyung Sohn</last_name>
    <phone>+82‐31‐920‐1636</phone>
    <email>gsgsbal@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jae Hwan Oh</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hwan Oh, MD,PHD</last_name>
      <phone>+82‐31‐920‐1637</phone>
      <email>jayoh@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Dae Kyung Sohn, MD,PHD</last_name>
      <phone>+82‐31‐920‐1636</phone>
      <email>gsgsbal@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jae Hwan Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Jae Hwan Oh</investigator_full_name>
    <investigator_title>Head of Center for Colorectal Cancer, National Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Rectal Neoplasms</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
